Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy
- 1 April 2005
- journal article
- case report
- Published by Wiley in Muscle & Nerve
- Vol. 31 (4) , 510-515
- https://doi.org/10.1002/mus.20244
Abstract
Rituximab, a monoclonal antibody against B-cell membrane marker CD-20, is an effective treatment for immunoglobulin M (IgM) monoclonal anti-myelin-associated glycoprotein (MAG) neuropathies. We report a patient with an autonomic and painful sensory neuropathy associated with an IgM lambda monoclonal gammopathy, responsive to rituximab. Treatment resulted in a decline in total IgM and improvement in the patient's painful neuropathy and dysautonomia. Rituximab may be an effective and tolerable treatment for autonomic and sensory neuropathy associated with IgM monoclonal gammopathy.Keywords
This publication has 15 references indexed in Scilit:
- Chronic neuropathy with IgM anti-ganglioside antibodies: Lack of long term response to rituximabNeurology, 2003
- Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapyArthritis & Rheumatism, 2003
- Treatment of IgM antibody associated polyneuropathies using rituximabJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodiesMuscle & Nerve, 2003
- Autonomic neuropathiesCurrent Opinion in Neurology, 2002
- Detection of anti-ganglioside antibodies in Guillain-Barré syndrome and its variants by the agglutination assayJournal of the Neurological Sciences, 2002
- Autoantibodies to Ganglionic Acetylcholine Receptors in Autoimmune Autonomic NeuropathiesNew England Journal of Medicine, 2000
- Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophyNeurology, 1996
- “Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-UpMayo Clinic Proceedings, 1993
- IgM PARAPROTEIN REACTIVE WITH MUSCLE ANTIGENS ASSOCIATED WITH AUTONOMIC AND PERIPHERAL NEUROPATHYBritish Journal of Haematology, 1989